Anterios

New York, United States Founded: 2006 • Age: 20 yrs Acquired By Allergan
Botulinum-based products for dermatology and aesthetics are developed.

About Anterios

Anterios is a Healthcare company based in New York (United States) founded in 2006 by Robert Nicolosi and Jonathan T Edelson, and was acquired by Allergan in January 2016. Botulinum-based products for dermatology and aesthetics are developed. Anterios has raised $26.9 million across 7 funding rounds from investors including Allergan, Ascent Biomedical Ventures and DRW Trading Group. Its chief executive, as recorded, is Jonathan T Edelson. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Anterios Inc. Its competitors include Avidity Biosciences, Revance Therapeutics and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.

Company details

Anterios was a clinical stage company developing novel delivery technologies and formulations for neurotoxins through skin. Anterios NDS proprietary platform delivery technology enables local, targeted delivery of neurotoxins through the skin without the need for injections. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. Its lead drug ANT-1207 is a topical formulation of botulinum toxin type A for the potential treatment of hyperhidrosis (excessive sweating), acne, and crows feet lines. The company has completed a pair of Phase II studies in acne, crows feet lines and Hyperhidrosis, according to ClinicalTrials.gov. The company was acquired by Allergan in Jan 2016, before which it spun out its other assets, including an injectable botulinum, into a new firm called Eirion Therapeutics.

Key Metrics
  • Total Equity Funding
    $26.9M (USD)

    in 7 rounds

  • Latest Funding Round
    $8.5M (USD), Series A

    Apr 2013

  • Investors
    Allergan

    & 6 more

  • Acquired by
    Allergan

    (Jan 2016)

Apps and channels of Anterios

its YouTube channel AbbVie has 56 subscribers and 30 videos.

AbbVie
YouTube 56 subscribers 30 videos Science & Technology
Open channel

Videos from Anterios

The most watched videos on Anterios's YouTube channel, AbbVie (56 subscribers). Click a video to play it here.

Make a Difference Working at AbbVie
5.4K views
How AbbVie Uses Technology to Accelerate Drug Development for Patients
3.6K views
AbbVie Employees Share Their Stories Living with Migraine
2.5K views
Internships at AbbVie
2.3K views

More on AbbVie.

Funding Insights of Anterios

Anterios has successfully raised a total of $26.9M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $8.5 million completed in April 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $26.9M
  • Total Rounds 7
  • Last Round Series A β€” $8.5M
  • First Round $5.95M

    (Jun 2007)

  • Investors Count 6

All 7 funding rounds of Anterios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2013$8.5MSeries A–Ascent Biomedical Ventures, DRW Trading Group
–
Jul 2011$3.04MSeries A––
–
Dec 2010$2MSeries A––
–
Sep 2010$750,000Series A––
–
Feb 2010$1.5MSeries A––
–
Oct 2009$5.17MSeries A––
–
Jun 2007$5.95MSeries A––
–
Valuation history

7 investors in total: 7 institutional.

Investors in Anterios

Anterios has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Allergan, Ascent Biomedical Ventures and DRW Trading Group.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
abvlp.com
quantumtp.com
A venture capital firm focused on early-stage MedTech investments.
2006shdpartners.comDallas, United States
A single-family office with diverse investment portfolios is operated.
2002spring-bay.comPonte Vedra Beach, United States
Diversified trading firm providing liquidity and technology solutions in finance.
1992drw.comChicago, United States
Functions as a hedge fund focused on investment strategies.
1999praesideo.comOgden, United States
A portfolio of generic medicines is developed and manufactured.
1948allergan.comMadison, United States
Premium access

Investor details for Anterios

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Anterios

2 people are tracked at Anterios (2 in leadership).

NameRoleGroup
Robert Nicolosi
Co-FounderLeadership
Jonathan T Edelson
Co-Founder & CEOLeadership
Premium access

Complete people profiles for Anterios

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Anterios

4 dated milestones of Anterios across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Anterios is founded.
  2. Funding First funding round of $6.0M.
  3. Funding Latest funding round, Series A, of $8.5M.
  4. Exit Acquired by Allergan.

Competitors of Anterios

Anterios has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Revance Therapeutics and Sutro Biopharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
revance.com2002Newark, United States$154.56M597
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Premium access

Detailed competitors of Anterios

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Anterios (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Anterios

Premium access

Complete news archive for Anterios

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anterios

Anterios was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Anterios is headquartered in New York, United States. It is registered at New York, New York, United States.

Jonathan T Edelson is the CEO of Anterios, as recorded in our data. They have also founded this company.

Anterios is a funded company, having raised a total of $26.9M across 7 funding rounds to date. The company's 1st funding round was a Series A of $5.95M, raised on Jun 2007.

Anterios was a clinical stage company developing novel delivery technologies and formulations for neurotoxins through skin. Anterios NDS proprietary platform delivery technology enables local, targeted delivery of neurotoxins through the skin without the need for injections. NDS also enables the formulation of macromolecules as ready-to-use liquid injectable products. Its lead drug ANT-1207 is a topical formulation of botulinum toxin type A for the potential treatment of hyperhidrosis (excessive sweating), acne, and crows feet lines. The company has completed a pair of Phase II studies in acne, crows feet lines and Hyperhidrosis, according to ClinicalTrials.gov. The company was acquired by Allergan in Jan 2016, before which it spun out its other assets, including an injectable botulinum, into a new firm called Eirion Therapeutics.

Anterios's top competitors include Revance Therapeutics, Sutro Biopharma and Avidity Biosciences.

Anterios has 7 investors. Key investors include Allergan, Ascent Biomedical Ventures, DRW Trading Group, Praesideo Management, and Quantum Technology Partners.

Anterios operates through Anterios Inc.

Yes. Anterios was acquired by Allergan in January 2016.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available